Skip to main content

Biology of Agomelatine: an open-label study of Agomelatine in adults with Major Depressive Disorder

This study aims to identify biomarkers that could help predict response to an established medication treatment for depression.

We are seeking males and females aged 18 to under 75 years of age with a diagnosis of major depression disorder to be involved in our study. This study aims to identify biomarkers that could help predict response to an established medication treatment for depression.

You will be required to take a daily dose of a locally approved medication for 8 weeks, with an optional follow up visit after 16 weeks.

A non-invasive EEG will be used to record your brainwaves three times throughout the study period. You will be required to complete a series of questionnaires at each research appointment and have an interview with one of the study clinicians. The study also involves a genetic saliva sample and laboratory blood tests. All data collected will be de-identified. 

To participate in this study, you must be fluent in English, able to provide informed consent and you must not be pregnant or breastfeeding. Additional eligibility criteria may apply.

Ethics committee approval number: 2020/ETH0214

 

Eligibility

You may be eligible to participate in this study if you:

  • have moderate to severe Major Depressive Disorder
  • are 18 to <75 years of age
  • are fluent in English
  • for the current depressive episode, must have failed < 3 prior antidepressant medications, and you must remain on your last failed currently prescribed antidepressant medication 
  • have no ECT or TMS treatment in the current episode
  • have no drug or alcohol dependence
  • (females) should not be pregnant

How to participate

If you are interested in assisting with this important and exciting area of research, please contact the study facilitator:

Clinical Trial Coordinator Ana Rita Barreiros on +61(2)86273319 or ana.barreiros@sydney.edu.au